Toll Free: 1-888-928-9744

Nippon Shinyaku Co., Ltd. - Product Pipeline Review - 2015

Published: Oct, 2015 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nippon Shinyaku Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Nippon Shinyaku Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Nippon Shinyaku Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nippon Shinyaku Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nippon Shinyaku Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nippon Shinyaku Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Nippon Shinyaku Co., Ltd.'s pipeline products

Reasons to Buy

- Evaluate Nippon Shinyaku Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nippon Shinyaku Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nippon Shinyaku Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nippon Shinyaku Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nippon Shinyaku Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Nippon Shinyaku Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Nippon Shinyaku Co., Ltd. Snapshot 5 Nippon Shinyaku Co., Ltd. Overview 5 Key Information 5 Key Facts 5 Nippon Shinyaku Co., Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Nippon Shinyaku Co., Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Nippon Shinyaku Co., Ltd. - Pipeline Products Glance 12 Nippon Shinyaku Co., Ltd. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 Nippon Shinyaku Co., Ltd. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Nippon Shinyaku Co., Ltd. - Drug Profiles 16 selexipag 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 prulifloxacin 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 afacifenacin 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 NS-141 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 NS-018 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 NS-065 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 NS-580 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Nippon Shinyaku Co., Ltd. - Pipeline Analysis 25 Nippon Shinyaku Co., Ltd. - Pipeline Products by Target 25 Nippon Shinyaku Co., Ltd. - Pipeline Products by Route of Administration 26 Nippon Shinyaku Co., Ltd. - Pipeline Products by Molecule Type 27 Nippon Shinyaku Co., Ltd. - Pipeline Products by Mechanism of Action 28 Nippon Shinyaku Co., Ltd. - Recent Pipeline Updates 29 Nippon Shinyaku Co., Ltd. - Dormant Projects 31 Nippon Shinyaku Co., Ltd. - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 NS-8 32 prulifloxacin 32 selexipag 32 Nippon Shinyaku Co., Ltd. - Company Statement 33 Nippon Shinyaku Co., Ltd. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Nippon Shinyaku Co., Ltd., Key Information 5 Nippon Shinyaku Co., Ltd., Key Facts 5 Nippon Shinyaku Co., Ltd. - Pipeline by Indication, 2015 7 Nippon Shinyaku Co., Ltd. - Pipeline by Stage of Development, 2015 8 Nippon Shinyaku Co., Ltd. - Monotherapy Products in Pipeline, 2015 9 Nippon Shinyaku Co., Ltd. - Partnered Products in Pipeline, 2015 10 Nippon Shinyaku Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 11 Nippon Shinyaku Co., Ltd. - Pre-Registration, 2015 12 Nippon Shinyaku Co., Ltd. - Phase III, 2015 13 Nippon Shinyaku Co., Ltd. - Phase II, 2015 14 Nippon Shinyaku Co., Ltd. - Phase I, 2015 15 Nippon Shinyaku Co., Ltd. - Pipeline by Target, 2015 25 Nippon Shinyaku Co., Ltd. - Pipeline by Route of Administration, 2015 26 Nippon Shinyaku Co., Ltd. - Pipeline by Molecule Type, 2015 27 Nippon Shinyaku Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 28 Nippon Shinyaku Co., Ltd. - Recent Pipeline Updates, 2015 29 Nippon Shinyaku Co., Ltd. - Dormant Developmental Projects,2015 31 Nippon Shinyaku Co., Ltd. - Discontinued Pipeline Products, 2015 32 Nippon Shinyaku Co., Ltd., Other Locations 34 Nippon Shinyaku Co., Ltd., Subsidiaries 36



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify